Oct 03rd 2013 - Edison Investment Research today published a report on Bionor Pharma ASA (BIONOR.L, LSE:BIONOR, LON:BIONOR) entitled "Aiming High In HIV". In summary, the report says:
Bionor Pharma’s ambitious aim to develop Vacc-4x as the first functional cure for HIV is supported by previous data and collaborations with leading institutes. A comprehensive ‘Kick, Kill and Boost’ strategy is in place and recent funding should allow Bionor to take Vacc-4x through the critical steps prior to partnering. Key ‘Kill’ and ‘Boost’ data are expected in Q214. We value Bionor at NOK4.0/share, based on prudent Vacc-4x assumptions.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »